Literature DB >> 30478217

Buprenorphine-naloxone.

Tina Hu1, Larry Nijmeh2, Adam Pyle2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30478217      PMCID: PMC6246048          DOI: 10.1503/cmaj.180776

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

2.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

3.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

4.  Home buprenorphine/naloxone induction in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Marc N Gourevitch
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.